Checkpoint Inhibitors and Induction of Celiac Disease-like Condition
Immune checkpoint inhibitors herald a new era in oncological therapy-resistant cancer, thus bringing hope for better outcomes and quality of life for patients. However, as with other medications, they are not without serious side effects over time. Despite this, their advantages outweigh their disad...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/3/609 |
| _version_ | 1797472743863615488 |
|---|---|
| author | Aaron Lerner Carina Benzvi |
| author_facet | Aaron Lerner Carina Benzvi |
| author_sort | Aaron Lerner |
| collection | DOAJ |
| description | Immune checkpoint inhibitors herald a new era in oncological therapy-resistant cancer, thus bringing hope for better outcomes and quality of life for patients. However, as with other medications, they are not without serious side effects over time. Despite this, their advantages outweigh their disadvantages. Understanding the adverse effects will help therapists locate, apprehend, treat, and perhaps diminish them. The major ones are termed immune-related adverse events (irAEs), representing their auto-immunogenic capacity. This narrative review concentrates on the immune checkpoint inhibitors induced celiac disease (CD), highlighting the importance of the costimulatory inhibitors in CD evolvement and suggesting several mechanisms for CD induction. Unraveling those cross-talks and pathways might reveal some new therapeutic strategies. |
| first_indexed | 2024-03-09T20:05:34Z |
| format | Article |
| id | doaj.art-25dc7453c27e47428813359a342e9bd9 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T20:05:34Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-25dc7453c27e47428813359a342e9bd92023-11-24T00:32:43ZengMDPI AGBiomedicines2227-90592022-03-0110360910.3390/biomedicines10030609Checkpoint Inhibitors and Induction of Celiac Disease-like ConditionAaron Lerner0Carina Benzvi1Chaim Sheba Medical Center, The Zabludowicz Research Center for Autoimmune Diseases, Research Department, Ramat Gan 52621, IsraelChaim Sheba Medical Center, The Zabludowicz Research Center for Autoimmune Diseases, Research Department, Ramat Gan 52621, IsraelImmune checkpoint inhibitors herald a new era in oncological therapy-resistant cancer, thus bringing hope for better outcomes and quality of life for patients. However, as with other medications, they are not without serious side effects over time. Despite this, their advantages outweigh their disadvantages. Understanding the adverse effects will help therapists locate, apprehend, treat, and perhaps diminish them. The major ones are termed immune-related adverse events (irAEs), representing their auto-immunogenic capacity. This narrative review concentrates on the immune checkpoint inhibitors induced celiac disease (CD), highlighting the importance of the costimulatory inhibitors in CD evolvement and suggesting several mechanisms for CD induction. Unraveling those cross-talks and pathways might reveal some new therapeutic strategies.https://www.mdpi.com/2227-9059/10/3/609celiac diseaseimmune checkpoint inhibitorNivolumabPD-1IpilimumabCLTA-4 |
| spellingShingle | Aaron Lerner Carina Benzvi Checkpoint Inhibitors and Induction of Celiac Disease-like Condition Biomedicines celiac disease immune checkpoint inhibitor Nivolumab PD-1 Ipilimumab CLTA-4 |
| title | Checkpoint Inhibitors and Induction of Celiac Disease-like Condition |
| title_full | Checkpoint Inhibitors and Induction of Celiac Disease-like Condition |
| title_fullStr | Checkpoint Inhibitors and Induction of Celiac Disease-like Condition |
| title_full_unstemmed | Checkpoint Inhibitors and Induction of Celiac Disease-like Condition |
| title_short | Checkpoint Inhibitors and Induction of Celiac Disease-like Condition |
| title_sort | checkpoint inhibitors and induction of celiac disease like condition |
| topic | celiac disease immune checkpoint inhibitor Nivolumab PD-1 Ipilimumab CLTA-4 |
| url | https://www.mdpi.com/2227-9059/10/3/609 |
| work_keys_str_mv | AT aaronlerner checkpointinhibitorsandinductionofceliacdiseaselikecondition AT carinabenzvi checkpointinhibitorsandinductionofceliacdiseaselikecondition |